About Multiple Myeloma
Our program utilizes a collaborative, multi-disciplinary team approach—we believe that is the best way to treat you as a whole person and address your health care needs in a comprehensive fashion. In addition to hematology and medical oncology physicians with vast experience in multiple myeloma and related diseases, the team includes skilled nurse practitioners, physician assistants, registered nurses, clinical social workers, nutritionists, and pharmacists. The team also includes leading experts from Mount Sinai’s Bone Marrow Transplant Program and specialists from other clinical services such as pathology, radiology, immunology, genomics, infectious diseases, orthopedic surgery, cardiology, and nephrology. As a patient at Mount Sinai, you have access to the finest specialists.
Our program is led by highly-regarded world experts in multiple myeloma. Sundar Jagannath, MD, Director, and Bart Barlogie, MD, Director of Myeloma Research, each have more than 30 years of experience researching and treating myeloma. In 1989, they established the first program ever entirely dedicated to myeloma research and patient care at the University of Arkansas, applying their expertise in hematology and oncology, pathology, and bone marrow transplantation to transform myeloma from an incurable disease to one that could be managed and controlled with innovative therapy approaches. They introduced autologous stem cell transplantation for myeloma and developed “Total Therapy” clinical trials, the first curative therapy for myeloma that employed all active agents up-front. They achieved remarkable improvements in survival and established new standards of care that have been adopted worldwide.
Dr. Jagannath joined Mount Sinai in 2010, from the now-closed St. Vincent’s Hospital-Manhattan. Dr. Barlogie joined Mount Sinai in 2015, following a lengthy career in Arkansas during which he made many notable contributions, including the use of genomic profiling for identification of risk-stratified disease subgroups, introduction of novel imaging techniques for myeloma staging and response assessment, and establishment of reproducible prognostic models. Together, they continue to advance innovative translational research and clinical care and mentor a team of outstanding myeloma physicians, with the goals of improving patient outcomes and achieving cure.
We are an integral part of Mount Sinai Cancer, including The Tisch Cancer Institute, which is a National Cancer Institute-Designated Cancer Center. This designation recognizes our standards of excellence and breakthrough accomplishments in research aimed at prevention and cure.
We welcome patients from the local region and across the United States, as well as international patients. We are committed to meeting the individual needs of each patient in an environment of compassion, comfort, and excellence.